William Blair analyst Myles Minter has maintained their bullish stance on SLN stock, giving a Buy rating on October 10.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Myles Minter has given his Buy rating due to a combination of factors that highlight the potential of Silence Therapeutics’ innovative mRNAi GOLD platform and the promising outlook for the company’s pipeline. The upcoming completion of the Phase II SANRECO study for divesiran in polycythemia vera (PV) by the end of 2025, with significant data expected in the second half of 2026, positions Silence Therapeutics to potentially differentiate itself from competitors like Protagonist and Takeda. This differentiation is a key factor in the positive outlook for the company’s stock.
Minter also notes the importance of the Lp(a)HORIZON cardiovascular outcomes study, which could redefine the landscape for Lp(a)-lowering therapeutics. The results of this study are crucial for assessing the value of a potential big pharma partnership for zerlasiran, which is ready for Phase III trials. These developments, coupled with the company’s active participation in industry events like the William Blair Innovator Series, underscore the strategic initiatives that could drive a re-rating of Silence Therapeutics’ shares.
In another report released on October 10, H.C. Wainwright also reiterated a Buy rating on the stock with a $75.00 price target.